Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$48.87
-0.8%		$36.25
$25.36
▼
$49.88
$2.48B1.2789,839 shs444,340 shs
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
$9.15
+2.2%		$7.97
$1.47
▼
$10.05
$2.44B2.096.67 million shs2.62 million shs
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$79.45
-0.6%		$94.14
$78.65
▼
$118.01
$1.82B0.53278,944 shs164,309 shs
Surmodics, Inc. stock logo
SRDX
Surmodics
$42.98
+0.4%		$37.58
$25.87
▼
$43.00
$614.53M1.3269,318 shs5.34 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
+0.61%+10.07%+40.64%+71.05%+30.86%
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
-5.84%-0.83%+37.98%+95.73%+486.56%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
-2.32%-3.09%-16.35%-19.00%-20.30%
Surmodics, Inc. stock logo
SRDX
Surmodics
0.00%0.00%0.00%0.00%+15.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$48.87
-0.8%		$36.25
$25.36
▼
$49.88
$2.48B1.2789,839 shs444,340 shs
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
$9.15
+2.2%		$7.97
$1.47
▼
$10.05
$2.44B2.096.67 million shs2.62 million shs
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$79.45
-0.6%		$94.14
$78.65
▼
$118.01
$1.82B0.53278,944 shs164,309 shs
Surmodics, Inc. stock logo
SRDX
Surmodics
$42.98
+0.4%		$37.58
$25.87
▼
$43.00
$614.53M1.3269,318 shs5.34 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
+0.61%+10.07%+40.64%+71.05%+30.86%
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
-5.84%-0.83%+37.98%+95.73%+486.56%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
-2.32%-3.09%-16.35%-19.00%-20.30%
Surmodics, Inc. stock logo
SRDX
Surmodics
0.00%0.00%0.00%0.00%+15.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AtriCure, Inc. stock logo
ATRC
AtriCure
2.91
Moderate Buy$48.63-0.49% Downside
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
2.40
Hold$5.56-39.17% Downside
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.33
Hold$110.6039.21% Upside
Surmodics, Inc. stock logo
SRDX
Surmodics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest SRDX, LMAT, BFLY, and ATRC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $55.00
8/19/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
8/14/2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
8/5/2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$104.00 ➝ $94.00
8/5/2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Barrington Research logo
Barrington Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
8/3/2026
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/28/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D+)
7/28/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$55.00 ➝ $50.00
7/28/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$55.00 ➝ $50.00
7/24/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/21/2026
AtriCure, Inc. stock logo
ATRC
AtriCure
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$52.00
(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AtriCure, Inc. stock logo
ATRC
AtriCure
$569.62M4.36$0.31 per share156.49$9.89 per share4.94
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
$97.61M24.95N/AN/A$0.77 per share11.88
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$262.43M6.92$2.82 per share28.21$17.35 per share4.58
Surmodics, Inc. stock logo
SRDX
Surmodics
$120.80M5.09$0.49 per share87.04$8.33 per share5.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AtriCure, Inc. stock logo
ATRC
AtriCure
-$11.45M$0.21232.44108.59N/A1.85%2.34%1.77%11/4/2026 (Estimated)
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
-$77.06M-$0.29N/AN/AN/A-66.74%-33.99%-22.96%10/30/2026 (Estimated)
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$57.73M$2.8527.9225.062.3625.02%15.63%10.06%11/5/2026 (Estimated)
Surmodics, Inc. stock logo
SRDX
Surmodics
-$11.54M-$1.23N/A53.73N/A-14.59%-2.99%-1.99%N/A

Latest SRDX, LMAT, BFLY, and ATRC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.8070$0.74-$0.0670$0.74$71.47 million$70.38 million
7/30/2026Q2 2026
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
-$0.0350-$0.01+$0.0250-$0.05$29.16 million$32.61 million
7/23/2026Q2 2026
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.0017$0.18+$0.1817$0.18$151.80 million$153.60 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
N/AN/AN/AN/AN/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$1.001.26%+16.05%35.09%14 Years
Surmodics, Inc. stock logo
SRDX
Surmodics
N/AN/AN/AN/AN/A

Latest SRDX, LMAT, BFLY, and ATRC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
quarterly$0.251.21%8/20/20268/20/20269/3/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AtriCure, Inc. stock logo
ATRC
AtriCure
0.14
4.22
3.19
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
N/A
4.06
3.06
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
0.40
16.31
13.96
Surmodics, Inc. stock logo
SRDX
Surmodics
0.27
3.91
3.10

Institutional Ownership

CompanyInstitutional Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
37.85%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
84.64%
Surmodics, Inc. stock logo
SRDX
Surmodics
96.63%

Insider Ownership

CompanyInsider Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
4.00%
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
21.99%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
7.40%
Surmodics, Inc. stock logo
SRDX
Surmodics
8.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,30050.87 million48.83 millionOptionable
Butterfly Network, Inc. stock logo
BFLY
Butterfly Network
460266.29 million207.73 millionOptionable
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
49022.87 million21.18 millionOptionable
Surmodics, Inc. stock logo
SRDX
Surmodics
45014.30 million13.03 millionOptionable

Recent News About These Companies

Endologix Pounces on Surmodics' Thrombectomy System in Strategic Acquisition
May 20, 2026  |  mddionline.comM
Endologix purchases thrombectomy system from Surmodics
May 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/endologix-purchases-thrombectomy-system-surmodics-105146277.html
Endologix Acquires Pounce System from Surmodics
May 19, 2026  |  ocbj.comO
Surmodics Completes Transition to Private Ownership
February 7, 2026  |  newscase.comN
Biocoat Announces Formation of Surmodics Services & Technologies Division Following Merger and Divestiture Transactions
December 10, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/biocoat-announces-formation-surmodics-services-170700279.html
SurModics Completes Merger, Ends Credit Agreement
November 19, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/surmodics-completes-merger-ends-credit-agreement?utm_source=marketbeat.com&utm_medium=referral
Surmodics stock rises after FTC indicates no appeal of merger ruling
November 17, 2025  |  za.investing.comhttps://za.investing.com/news/stock-market-news/surmodics-stock-rises-after-ftc-indicates-no-appeal-of-merger-ruling-93CH-3988175
Surmodics’ acquisition will not be appealed by FTC
November 17, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/surmodics-acquisition-will-not-be-appealed-by-ftc/ar-AA1QB4d6
Surmodics gains as FTC won't appeal denial of GTCR deal injunction
November 17, 2025  |  msn.comhttps://www.msn.com/en-us/money/mergers-and-acquisitions/surmodics-gains-as-ftc-won-t-appeal-denial-of-gtcr-deal-injunction/ar-AA1QBqcF
Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today
November 17, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251117640716/en/Surmodics-Announces-FTC-Does-Not-Intend-to-Appeal-Denial-of-Injunction-Order-Preventing-Closing-Set-to-Expire-Today/
Barrington Research Downgrades Surmodics (SRDX)
November 15, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/barrington-research-downgrades-surmodics-srdx/ar-AA1Qu0w4
SurModics Merger with GTCR LLC Clears Legal Hurdle
November 12, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/surmodics-merger-with-gtcr-llc-clears-legal-hurdle?utm_source=marketbeat.com&utm_medium=referral
Surmodics Shares Skyrocket 50% After Court Rejects FTC Request to Block GTCR Acquisition
November 11, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/surmodics-shares-skyrocket-50-after-court-rejects-ftc-request-to-block-gtcr-acquisition/ar-AA1Qe6LM
GTCR can proceed with Surmodics acquisition after court denies FTC’s attempt to block it
November 11, 2025  |  massdevice.comhttps://www.massdevice.com/gtcr-proceed-surmodics-acquisition-ftc-court/
Surmodics surges after court denies injunction to block sale to GTCR
November 11, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/surmodics-surges-after-court-denies-injunction-to-block-sale-to-gtcr/ar-AA1QdXJq
Federal Judge Clears Path For GTCR's Takeover Of Surmodics After FTC Challenge
November 11, 2025  |  benzinga.comhttps://www.benzinga.com/m-a/25/11/48785094/federal-judge-clears-path-for-gtcrs-takeover-of-surmodics-after-ftc-challenge?utm_source=snapi
Surmodics confirms District Court denies request for preliminary injunction
November 11, 2025  |  msn.comhttps://www.msn.com/en-us/general/general/surmodics-confirms-district-court-denies-request-for-preliminary-injunction/ar-AA1QbZH5
US judge rejects FTC's bid to block private equity medical company deal
November 10, 2025  |  reuters.comhttps://www.reuters.com/world/us-judge-rejects-ftcs-bid-block-private-equity-medical-company-deal-2025-11-10/
Surmodics sale to GTCR approved by federal court
November 10, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/surmodics-sale-to-gtcr-approved-by-federal-court/ar-AA1QaSf7
Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR
November 10, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251110939371/en/surmodics-announces-u.s.-district-court-denies-request-for-preliminary-injunction-to-block-proposed-acquisition-by-gtcr/

New MarketBeat Followers Over Time

Media Sentiment Over Time

AtriCure stock logo

AtriCure NASDAQ:ATRC

$48.86 -0.42 (-0.84%)
As of 01:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Butterfly Network stock logo

Butterfly Network NYSE:BFLY

$9.14 +0.20 (+2.18%)
As of 01:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

LeMaitre Vascular stock logo

LeMaitre Vascular NASDAQ:LMAT

$79.45 -0.51 (-0.64%)
As of 01:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Surmodics stock logo

Surmodics NASDAQ:SRDX

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas